The White House has launched a new website, TrumpRx, which lists dozens of prescription drugs at steeply discounted prices. The site, part of President Trump's efforts to reduce direct-to-consumer drug costs, features deals with over a dozen pharmaceutical companies, including Pfizer and Novo Nordisk.
The discounts offered by TrumpRx are significantly lower than list prices, with some examples showing reductions of up to 83%. For instance, a four-week supply of Wegovy injection pens is listed at $199 for the first two months and $349 after that, compared to a list price of $1,349.02.
While the website claims to offer savings to patients, health experts argue that most people with insurance will still pay higher prices due to co-pays. Dr. Mehmet Oz, administrator of the Centers for Medicare and Medicaid Services, has urged patients to check TrumpRx before purchasing medication, suggesting it could be a game-changer for those without coverage or with high deductibles.
TrumpRx is part of the president's broader push to reduce pharmaceutical costs. Beyond TrumpRx, he has signed deals with several companies to offer their drugs to Medicaid patients at most-favored-nation prices, and agreed to introduce similar pricing for new drugs introduced in the US.
However, critics argue that these efforts will not significantly impact prices for most Americans, as many people pay out-of-pocket only for medications. Furthermore, pharmaceutical companies have raised list prices of 947 brand-name drugs this January, with some increases exceeding inflation rates.
Despite these concerns, TrumpRx has sparked a stir in the healthcare community, with some experts hailing it as a transformative initiative and others questioning its effectiveness.
The discounts offered by TrumpRx are significantly lower than list prices, with some examples showing reductions of up to 83%. For instance, a four-week supply of Wegovy injection pens is listed at $199 for the first two months and $349 after that, compared to a list price of $1,349.02.
While the website claims to offer savings to patients, health experts argue that most people with insurance will still pay higher prices due to co-pays. Dr. Mehmet Oz, administrator of the Centers for Medicare and Medicaid Services, has urged patients to check TrumpRx before purchasing medication, suggesting it could be a game-changer for those without coverage or with high deductibles.
TrumpRx is part of the president's broader push to reduce pharmaceutical costs. Beyond TrumpRx, he has signed deals with several companies to offer their drugs to Medicaid patients at most-favored-nation prices, and agreed to introduce similar pricing for new drugs introduced in the US.
However, critics argue that these efforts will not significantly impact prices for most Americans, as many people pay out-of-pocket only for medications. Furthermore, pharmaceutical companies have raised list prices of 947 brand-name drugs this January, with some increases exceeding inflation rates.
Despite these concerns, TrumpRx has sparked a stir in the healthcare community, with some experts hailing it as a transformative initiative and others questioning its effectiveness.